Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App





New Study Reveals Rapid Sepsis Test Drives 56% Boost in ED Discharges

By LabMedica International staff writers
Posted on 31 Jul 2025

Every year, emergency departments (EDs) in the United States record over 155 million visits, with around 20% of adults showing signs of potentially serious infections. More...

One of the most critical choices emergency clinicians must make is determining which of these patients has sepsis and which do not. In situations where time is of the essence, the ability to swiftly and accurately rule out sepsis can significantly influence patient outcomes, the quality of care, hospital finances, and the overall efficiency of the healthcare system.

At the same time, overcrowding in EDs continues to put pressure on hospital operations and affect patient satisfaction. Over a 12-month span, average ED boarding times rose from 167 to 175 minutes, while the percentage of patients leaving without being seen increased from 1.1% to 2.1%, raising serious safety concerns. In such a context, being overly cautious and admitting patients out of concern for sepsis—though done with good intentions—can worsen crowding and slow down treatment for others, including those who are actually septic. Now, new multicenter study data presented at ADLM 2025 reveal that targeted sepsis testing at triage in the ED may be key to preserving inpatient bed capacity for the most severe patients.

Cytovale’s (San Francisco, CA, USA) IntelliSep is a rapid diagnostic tool for sepsis that supports emergency clinicians in making more confident decisions by quickly assessing patients’ sepsis risk. This U.S. Food and Drug Administration-cleared diagnostic, which provides results in roughly eight minutes from a standard blood draw, can be used at the triage stage to stratify patients based on their risk. The quick results help clinicians distinguish those who can be safely discharged from those needing urgent care and possible hospitalization. The study shared at ADLM 2025 involved 4,650 patients showing signs and symptoms of infection, who were tested with IntelliSep over a four-month period at four hospitals.

Using IntelliSep's rapid host-response test led to a 56% relative increase in discharges from the ED among patients identified as low risk, while simultaneously reducing the use of inpatient beds—without causing a rise in return visits. By applying this risk assessment tool early during triage, clinicians were able to avoid unnecessary admissions and discharge patients more confidently. The findings emphasize that smarter, data-driven sepsis evaluations at triage can have a direct effect on hospital capacity by boosting the number of safe discharge decisions.

Related Links:
Cytovale


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Pipette Calibration System
Artel PCS®
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.